LIXTE Biotechnology (LIXT) announced it has received a letter from the Nasdaq Hearings Panel stating that the Company has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), the “Equity Rule,” requiring a minimum equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The Nasdaq letter follows LIXTE’s closing of a $5.0 million placement and a $1.5 million registered direct offering, announced on July 2, 2025, and July 8, 2025, respectively.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT: